Results for "consumer data right"
411-420 of 515 results for 'consumer data right'
Four key ways technology will help companies meet their decarbonisation goals
Companies know they have to change the way they operate if they're going to reach net zero by 2050. In this Insight, we explore four key ways technology can help meet decarbonisation goals, drawing on examples discussed in our recent webinar 'Leveraging technology to accelerate decarbonisation'. ...
ASIC ramps up greenwashing-related regulatory interventions, targeting managed funds and ASX listed entities
ASIC's latest report, ASIC's recent greenwashing interventions (the Report), outlines its recent surveillance activities and regulatory interventions to tackle misleading marketing and greenwashing. ...
The pitfalls of pre-emptive rights
In this Insight, we consider an alternative approach that may better balance the rights of selling and non-selling investors where a pre-emptive right remains appropriate. ...
FIRB changes to note from 1 July 2023
In this Insight, we outline and comment on the New Register and corresponding reporting obligations. ...
ASIC's New Document Production Guidelines
ASIC has released its new Document Production Guidelines, which govern how it expects electronic and hard copy records to be produced in response to compulsory notices. ...
Dollars and sense: the evolution of executive remuneration practices
The need for robust executive remuneration frameworks is becoming increasingly important as companies tackle the challenges arising out of the COVID-19 pandemic, a heightened regulatory environment and the need to strike the right balance with executives to drive and reward conduct and performance t ...
What Aristocrat means for computer-implemented patents
Software companies such as Atlassian, Canva and Rokt are hailed as success stories of Australian innovation. However, for at least the past decade, it has been difficult to protect the value of invest ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
Regulatory scrutiny of private capital increases
Private capital is becoming a growing focus of regulators, both in Australia and internationally, given the ever-increasing flow of capital to the sector in recent years. ...